Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.68 |
| ▸ | POLG | P54098 | 1/20 | 0.58 |
| ▸ | POLA1 | P09884 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-C-Methylcytidine Triphosphate SCHEMBL18561540 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL18561539 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14853857 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL4454623 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537440 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929175 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537067 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21007902 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21006164 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19558282 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-9809616-B2 | Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer | EMORY UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY2 558/4885P2RY4 427/4885POLG 349/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY2 558/4885P2RY4 427/4885POLG 349/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY2 558/4885P2RY4 427/4885POLG 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.